US FDA found potential ongoing problems with corrective actions, test validation and other regulatory issues during an April inspection of Zimmer Biomet Holdings Inc.’s North Campus manufacturing facility in Warsaw, Ind. The company disclosed the inspection results in a May 16 statement.
The agency’s 2016 inspection of the North Campus facility found similar issues that resulted in a 58-page, 14-count FDA Form-483. At the time, Zimmer Biomet said the identified issues predated...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?